Findings

What do systematic reviews say?

140 questions · 146 findings · 18 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 32 · 21.9%GRADE not reported 16 · 11%Very low 23 · 15.8%Low 51 · 34.9%Moderate 24 · 16.4%High 0 · 0%

Interferon‐α alone vs interferon‐α plus bevacizumab

Quality of life · previously untreated patients with mRCC

The review found no eligible studies for this question.

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Interferon‐α alone vs interferon‐α plus bevacizumab

Adverse events (grade ≥ 3) · previously untreated patients with mRCC

Interferon‐α alone probably leads to lower adverse events (grade ≥ 3) compared with interferon‐α plus bevacizumab (moderate certainty).

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 0.77 [0.71, 0.84]
2 studies · 1350 participants
Moderate

Peginterferon plus ribavirin vs non‐pegylated interferon plus ribavirin

All‐cause mortality or liver‐related morbidity · people with chronic hepatitis C

Peginterferon plus ribavirin showed no clear difference in liver‐related morbidity plus all‐cause mortality compared with non‐pegylated interferon plus ribavirin (low certainty).

1 finding from 1 review

Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C 2014 · Cochrane Headline outcomes only
OR 1.14 [0.38, 3.42]
1789 participants
Low

Peginterferon plus ribavirin vs non‐pegylated interferon plus ribavirin

Discontinuation of medication due to adverse events · people with chronic hepatitis C

Peginterferon plus ribavirin showed no clear difference in adverse events leading to treatment discontinuation compared with non‐pegylated interferon plus ribavirin (low certainty).

1 finding from 1 review

Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C 2014 · Cochrane Headline outcomes only
RR 0.86 [0.68, 1.09]
15 studies · 4571 participants
Low

Peginterferon plus ribavirin vs non‐pegylated interferon plus ribavirin

Sustained virological response · people with chronic hepatitis C

It is very uncertain whether peginterferon plus ribavirin changes sustained virological response compared with non‐pegylated interferon plus ribavirin (very low certainty).

1 finding from 1 review

Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C 2014 · Cochrane Headline outcomes only
RR 1.39 [1.25, 1.56]
27 studies · 6104 participants
Very low

Type I Interferons vs placebo

Remission · patients with induction of remission in ulcerative colitis

Type I Interferons showed no clear difference in remission compared with placebo (moderate certainty).

1 finding from 1 review

Type I interferons for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.16 [0.84, 1.58]
4 studies · 362 participants
Moderate

Type I Interferons vs placebo

Clinical improvement · patients with induction of remission in ulcerative colitis

Type I Interferons showed no clear difference in clinical improvement compared with placebo (moderate certainty).

1 finding from 1 review

Type I interferons for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.16 [0.96, 1.4]
4 studies · 425 participants
Moderate

Type I Interferons vs placebo

Serious adverse events · patients with induction of remission in ulcerative colitis

Type I Interferons showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Type I interferons for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 0.74 [0.13, 4.14]
4 studies · 468 participants
Low

Type I Interferons vs placebo

Withdrawals due to adverse events · patients with induction of remission in ulcerative colitis

Type I Interferons may leads to higher withdrawals due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Type I interferons for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 3.16 [1.06, 9.4]
4 studies · 394 participants
Low

Interferon beta‐1a vs placebo

Improved IBDQ at week 8 · people with active UC

Interferon‐B‐1a showed no clear difference in improved IBDQ at week 8 compared with placebo (moderate certainty).

1 finding from 1 review

The impact of biological interventions for ulcerative colitis on health‐related quality of life 2015 · Cochrane Headline outcomes only
RR 1.14 [0.8, 1.61]
1 study · 194 participants
Moderate

Statins plus beta interferon vs interferon beta‐1a

Relapse · Multiple sclerosis

It is very uncertain whether statins plus beta interferon changes number of participants with relapses at 12 months Number of… compared with beta interferon (very low certainty).

2 findings from 1 review

Statins for multiple sclerosis 2011 · Cochrane Headline outcomes only
RR 1 [0.45, 2.23]
1 study · 34 participants
Very low
Statins for multiple sclerosis 2011 · Cochrane Headline outcomes only
RR 0.7 [0.36, 1.36]
1 study · 45 participants
Very low

Statins plus beta interferon vs interferon beta‐1a

Number of participants with progression at 12 months3 ‐ not reported · Multiple sclerosis

The review found no eligible studies for this question.

1 finding from 1 review

Statins for multiple sclerosis 2011 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Statins plus beta interferon vs interferon beta‐1a

Number of participants with progression at 24 months Number of participants with progression at 24 months · Multiple sclerosis

It is very uncertain whether statins plus beta interferon changes number of participants with progression at 24 months Number of… compared with beta interferon (very low certainty).

1 finding from 1 review

Statins for multiple sclerosis 2011 · Cochrane Headline outcomes only
RR 0.13 [0.01, 2.22]
1 study · 45 participants
Very low

Statins plus beta interferon vs interferon beta‐1a

Number of participants with new T2 or GELs at 12 months Number of participants with new T2 or GELs at 12 months · Multiple sclerosis

It is very uncertain whether statins plus beta interferon changes number of participants with new T2 or GELs at 12 months Number of… compared with beta interferon (very low certainty).

1 finding from 1 review

Statins for multiple sclerosis 2011 · Cochrane Headline outcomes only
RR 1 [0.3, 3.36]
1 study · 34 participants
Very low

Statins plus beta interferon vs interferon beta‐1a

Number of participants with new T2 or GELs at 24 months3 ‐ not reported · Multiple sclerosis

The review found no eligible studies for this question.

1 finding from 1 review

Statins for multiple sclerosis 2011 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Statins plus beta interferon vs interferon beta‐1a

Change in disability Assessed by: EDSS · Multiple sclerosis

1 finding from 1 review

Statins for multiple sclerosis 2011 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 387 participants
Moderate

Pegylated (PEG) interferon alpha‐2a vs standard interferon

Sustained virological response · patients on HD with HCV infection

Pegylated interferon alpha‐2a showed no clear difference in sustained virological response 6 months after stopping treatment compared with standard interferon (low certainty).

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
RR 2.4 [0.99, 5.81]
1 study · 50 participants
Low

Pegylated (PEG) interferon alpha‐2a vs standard interferon

Treatment discontinuation · patients on HD with HCV infection

Pegylated interferon alpha‐2a showed no clear difference in treatment discontinuation compared with standard interferon (low certainty).

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
RR 0.11 [0.01, 1.96]
1 study · 50 participants
Low

Pegylated (PEG) interferon alpha‐2a vs standard interferon

Adverse events · patients on HD with HCV infection

Pegylated interferon alpha‐2a showed no clear difference in adverse events compared with standard interferon (low certainty).

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
RR 0.11 [0.01, 1.96]
1 study · 50 participants
Low

Pegylated (PEG) interferon alpha‐2a vs standard interferon

Death · patients on HD with HCV infection

Pegylated interferon alpha‐2a showed no clear difference in death compared with standard interferon (low certainty).

1 finding from 1 review

Interventions for dialysis patients with hepatitis C virus (HCV) infection 2023 · Cochrane Headline outcomes only
RR 0.33 [0.01, 7.81]
1 study · 50 participants
Low